Following DongKook Pharmaceutical, its subsidiary DongKook Life Science is also pushing to change its corporate name. The company plans to embed the expertise of its existing contrast agent business into the new name and expand its business scope into new drug development and contract manufacturing organization (CMO) of pharmaceuticals.

DongKook Life Science announced on the 26th that it held a board meeting and resolved an agenda item to change its corporate name to “DK Luonix.” The company plans to convene an extraordinary general meeting of shareholders on December 11 to approve an amendment to its articles of association.

Previously, its parent company DongKook Pharmaceutical also decided on the 12th to change its corporate name to “DK Centellian.” DongKook Pharmaceutical plans to expand into the health and beauty sector based on its pharmaceuticals business and to strengthen its overseas market presence. The proposal to change the corporate name is scheduled to be approved at an extraordinary general meeting of shareholders on November 27.

The two companies will commonly use “DK” in their new names to represent the identity of the former DongKook Pharmaceutical. DK signifies the history and corporate tradition that DongKook Pharmaceutical has built over 58 years.

The new name of DongKook Life Science, “Luonix,” is said to combine “Luminous,” meaning shining; “On,” with the connotation of illuminating; and “technics,” representing technology. Reflecting the role of contrast agents, which clearly visualize body tissues and blood vessels during imaging diagnostics, the name is explained as conveying the meaning of “technology that illuminates light.”

DongKook Life Science has so far operated its business mainly around contrast agent pharmaceuticals used in domestic imaging diagnostics. Contrast agents are pharmaceuticals that help visualize specific tissues and blood vessels more clearly in magnetic resonance imaging (MRI) or computed tomography (CT) examinations.

The company plans to expand overseas its existing contrast agent business while pursuing domestic and international market entry for new MRI-related drugs. It will also foster the pharmaceutical CMO business as a new growth area. The company intends to diversify its operations by leveraging the technology and production capabilities accumulated in the imaging diagnostics field.

A DongKook Life Science official said, “The company will make a leap forward as a business that not only enhances competitiveness across a broader domain spanning the domestic and global imaging diagnostics markets, but also actively expands new businesses that serve as a foundation for future growth.”

Popular News